Skip to main content
SpringerLink
Log in

Pharmacokinetic study of IV infusions of adriamycin

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The plasma pharmacokinetics of adriamycin has been studied in 21 cancer patients (31–85 years old) without liver tumours after short (3.00 min) and prolonged (45 min-16h) i.v. infusions.

The area under the plasma concentration-time curve and the maximum plasma concentration compensated for dose variation showed a more than 3-fold individual variation. The pharmacokinetics of adriamycin was linear. There was no pharmacokinetic rational for variation of the dose with the age of the patients.

There was good agreement between the measured plasma concentration-time curves for prolonged infusions and curves predicted from pharmacokinetic data from short term infusions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Int Med 80: 249–259

    Google Scholar 

  2. Carter SK (1975) Adriamycin — A review. J Natl Cancer Inst 55: 1265–1274

    Google Scholar 

  3. Lenaz L, Page JA (1976) Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 3: 111–120

    Google Scholar 

  4. Minow RA, Benjamin RS, Lee ET, Gottlieb JA (1977) Adriamycin cardiomyopathy-risk factors. Cancer 39: 1397–1402

    Google Scholar 

  5. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, von Hoff Al, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Int Med 91: 710–717

    Google Scholar 

  6. Benjamin RS (1975a) Clinical pharmacology of adriamycin (NSC-123 127). Cancer Chemother Rep Part 3 6: 183–185

    Google Scholar 

  7. Benjamin RS (1975b) A practical approach to adriamycin (NSC-123 127) toxicology. Cancer Chemother Rep Part 3 6: 191–194

    Google Scholar 

  8. Benjamin RS, Riggs CE Jr, Bachur NR (1977) Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37: 1416–1420

    Google Scholar 

  9. Benjamin RS, Wiernik PH, Bachur NR (1974) Adriamycin chemotherapy. Efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 33: 19–27

    Google Scholar 

  10. Chan KK, Chlebowski RT, Tong M, Chen H-SG, Gross JF, Bateman JR (1980) Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res 40: 1263–1268

    Google Scholar 

  11. Chlebowski RT, Chan KK, Tong MJ, Weiner JM, Ryden VMJ, Bateman JR (1981) Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: Clinical and pharmacokinetic aspects. Cancer 48: 1088–1095

    Google Scholar 

  12. Ehninger G, Stocker H-J, Proksch B, Wilms K (1980) Die Pharmakokinetik von Adriamycin und Adriamycin-Metaboliten. Klin Wochenschr 58: 927–934

    Google Scholar 

  13. Eksborg S, Cedermark BJ, Strandler H-S (1985) Intrahepatic and intravenous administration of adriamycin — A comparative pharmacokinetic study in patients with malignant liver tumours. Med Onc Tumor Pharm 2: 47–54

    Google Scholar 

  14. Gil P, Favre R, Durand A, Iliadis A, Cano JP, Carcassone Y (1983) Time dependency of adriamycin and adriamycinol kinetics. Cancer Chemother Pharmacol 10: 120–124

    Google Scholar 

  15. Robert J, Illiadis A, Hoerni B, Cano J-P, Durand M, Lagarde C (1982) Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer Clin Oncol 18: 739–745

    Google Scholar 

  16. Boston RC, Phillips DR (1983) Evidence of possible dose-de-pendent doxorubicin plasma kinetics in man. Cancer Treat Rep 67: 63–69

    Google Scholar 

  17. Gil P, Favre R, Durand A, Iliadis A, Cano JP, Carcassone Y (1982) Time dependency of adriamycin. Pharmacocinétique de l'Adryamicine. Bull Cancer 69: 58

    Google Scholar 

  18. Powis G, Ames MM, Kovach JS (1981) Dose-dependent pharmacokinetics and cancer chemotherapy. Cancer Chemother Pharmacol 6: 1–9

    Google Scholar 

  19. Mattsson W, Borgström S, Landberg T (1982) A weekly schedule of low-dose doxorubicin in treatment of advanced breast cancer. Clin Therapeutics 5: 193–203

    Google Scholar 

  20. Weiss AJ, Metter GE, Fletcher WS, Wilson WL, Grage TB, Ramirez G (1976) Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 60: 813–822

    Google Scholar 

  21. Benjamin RS, Chawla SP, Ewer MS, Wallace S, Mackay B, Carrasco CH, Legha SS, Mann G, Hortobagyi GN, Valdivieso M, Ali MK, Haynie TP (1983) Cardiac toxicity of high-cumulative-dose adriamycin by rapid or 24–96 hour continuous infusion. Proc Am Soc Clin Oncol 2: C-159

  22. Gercovich FG, Praga C, Beretta G, Morgenfeld M, Muchnik J, Pesce R, Ho DHW, Benjamin RS (1979) Ten-hour continous infusion of adriamycin. Proc Am Soc Clin Oncol 20: 372

    Google Scholar 

  23. Hortobagyi G, Frye D, Blumenschein G, Ewer M, Mackay B, Buzdar A, Yap H, Hug V, Fraschini G, Benjamin R (1983) FAC with adriamycin by continuous infusion for treatment of advanced breast cancer. Proc Am Soc Clin Oncol 2: C-408

  24. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Int Med 96: 133–139

    Google Scholar 

  25. Legha SS, Benjamin RS, Mackay B, Yap HY, Wallace S, Ewer M, Blumenschein GR, Freireich EJ (1982) Adriamycin therapy by continous intravenous infusion in patients with metastatic breast cancer. Cancer 49: 1762–1766

    Google Scholar 

  26. Eksborg S, Ehrsson H, Wallin I, Lindfors A (1981) Quantitative determination of adriamycin and daunorubicin — handling of blood and plasma samples. Acta Pharm Suec 18: 215–220

    Google Scholar 

  27. Eksborg S, Ehrsson H, Andersson I (1979) Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol. J Chromatogr 164: 479–486

    Google Scholar 

  28. Wagner JG (1976) Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharm Biopharm 4: 443–467

    Google Scholar 

  29. Harris PA, Gross JF (1975) Preliminary pharmacokinetic model for adriamycin (NSC-123 127). Cancer Chemother Rep Part 1: 59: 819–825

    Google Scholar 

  30. Benjamin RS, Riggs CE Jr, Bachur NR (1973) Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther 14: 592–600

    Google Scholar 

  31. Robert J, Hoerni B (1983) Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 43: 4467–4469

    Google Scholar 

  32. Robert J, Vrignaud P, Iliadis A, Eghbali H, Hoerni B (1983) Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas. Nouv Rev Fr Hematol 25: 91–95

    Google Scholar 

  33. Gessner T, Robert J, Bolanowska W, Hoerni B, Durand M, Preisler H, Rustum J (1981) Effects of prior therapy on plasma levels of adriamycin during subsequent therapy. J Med 12: 183–193

    Google Scholar 

  34. Oosterbaan MJM, Dirks RJM, Vree TB, van der Kleijn E (1983) Clinical pharmacokinetics of adriamycin. Pharm Weekbl 5: 39

    Google Scholar 

  35. Tipping S, Riggs CE Jr, Egorin MJ, Whitacre M, Van Echo DA, Aisner J, Bachur NR (1982) Accelerated disappearance of doxorubicin (dox) and doxorubicinol (doxol) from plasma following prior chemotherapy. Proc Am Assoc Cancer Res 23: 132

    Google Scholar 

  36. Legha SS, Benjamin RS, Yap HY, Freireich EJ (1979) Augmentation of adriamycin's therapeutic index by prolonged continuous i.v. infusion for advanced breast cancer. Proc Am Assoc Cancer Res 20: 261

    Google Scholar 

  37. Baurain R, Deprez-De Campeneere D, Zenebergh A, Trouet A (1982) Plasma levels of doxorubicin after iv bolus injection and infusion of the doxorubicin-DNA complex in rabbits and man. Cancer Chemother Pharmacol 9: 93–96

    Google Scholar 

  38. DeGregorio MW, Carrera CJ, Klock JC, Pegelow CH, Wilbur JR (1982) Cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with acute leukemia. Cancer Treat Rep 66: 2085–2088

    Google Scholar 

  39. Eichholtz-Wirth H (1980) Dependence of the cytostatic effect of adriamycin on drug concentration and exposure time in vitro. Br J Cancer 41: 886–891

    Google Scholar 

  40. Lokich JJ, Perri J, Bothe A, Zipoli T, Philips D, Sonneborn H, Paul S, Green R (1983) Cancer chemotherapy via ambulatory infusion pump. Am J Clin Oncol 6: 355–363

    Google Scholar 

  41. Lokich J, Bothe A Jr, Fine N, Perri J (1982) The delivery of cancer chemotherapy by constant venous infusion — Ambulatory management of venous access and portable pump. Cancer 50: 2731–2735

    Google Scholar 

  42. Bern MM, McDermott W Jr, Cady B, Oberfield RA, Trey C, Clouse ME, Tullis JL, Parker LM (1978) Intraarterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma — A clinical and pharmacology report. Cancer 42: 399–405

    Google Scholar 

Download references

Author information

Author notes

  1. P. Tahvanainen

    Present address: Farmitalia Carlo Erba AB, P.O. Box 3511, S-183 03, Täby, Sweden

Authors and Affiliations

  1. Karolinska Pharmacy, Stockholm, Sweden

    S. Eksborg & H. -S. Strandler

  2. Radiumhemmet, Karolinska Hospital, Stockholm, Sweden

    F. Edsmyr, I. Näslund & P. Tahvanainen

Authors
  1. S. Eksborg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. -S. Strandler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Edsmyr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Näslund
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Tahvanainen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eksborg, S., Strandler, H.S., Edsmyr, F. et al. Pharmacokinetic study of IV infusions of adriamycin. Eur J Clin Pharmacol 28, 205–212 (1985). https://doi.org/10.1007/BF00609693

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00609693

Key words

Search

Navigation